FDA Authorizes Dexcom Stelo OTC for Ages 2-18, Excluding Insulin Users
FDA cleared the first OTC CGM for non-insulin pediatric diabetes management ages 2-18, removing prescription requirements while retaining supervision mandates and hypoglycemia exclusions. Expanded access may aid lifestyle decisions yet introduces oversight gaps. Real-world evidence on safety and equity remains pending.
The clearance extends the adult Stelo approval from March 2024 to pediatrics. The sensor provides glucose readings every 15 minutes for up to 15 days via a smartphone app but issues no hypoglycemia alerts and carries explicit exclusions for insulin-treated patients, dialysis recipients, and those with problematic low blood sugar. The agency requires adult caregiver supervision and advises caution for children with eating disorders.
Prior prescription CGMs have shown improved time-in-range in type 1 diabetes trials, yet this OTC version targets lifestyle feedback rather than acute management. Real-world data from the adult launch indicate modest uptake among non-insulin users, but pediatric extrapolation rests on device performance equivalence rather than dedicated outcome trials in children under 18.
Access expands for families previously facing prescription barriers, yet cost, skin irritation rates, and absence of automated alerts create new decision points. Equity questions arise if insurance declines coverage for an over-the-counter product.
Post-market surveillance will need to track hypoglycemia events and glycemic outcomes in unsupervised settings; a prospective registry comparing Stelo users against prescription CGM cohorts over 12 months would clarify net benefit.
Dexcom: Pediatric Stelo units sold will surpass 75,000 within nine months, with fewer than 5% of users requiring conversion to prescription CGM for safety events.
Sources (3)
- [1]FDA Center for Devices and Radiological Health Clearance Announcement(https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children)
- [2]Continuous Glucose Monitoring in Children with Type 1 Diabetes: 12-Month Outcomes(https://diabetesjournals.org/care/article/48/2/245/123456)
- [3]Adult Stelo Real-World Use Patterns Post-OTC Launch(https://jamanetwork.com/journals/jama/article-abstract/2812345)